FDA approves EPZICOM

Research Triangle Park, NC August 2, 2004 - EPZICOMTM, a new product combining two HIV medicines into one tablet dosed once a day (QD) with no food or fluid requirements, was cleared for prescription use today by the U.S. Food and Drug Administration (FDA). EPZICOM combines two widely-used nucleoside reverse transcriptase inhibitors (NRTIs), EPIVIR(R) (lamivudine, 3TC) and ZIAGEN(R) (abacavir sulfate, ABC) for use in combination with other antiretroviral drugs. The brand name, EPZICOM, is an acronym for EPIVIR and ZIAGEN in COMbination. EPZICOM Tablets are recommended for use in combination with antiretroviral drugs from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors.

GlaxoSmithKline (GSK), manufacturer of EPZICOM, announced today that it is initiating a voucher program for EPZICOM that will provide a 60 day supply of EPZICOM directly to patients at no cost. These vouchers will be available in limited supply through participating healthcare providers for a limited time. Vouchers can be used to initiate antiretroviral therapy for therapy-nave patients or for therapy-experienced patients who require a change in regimen.

"EPZICOM marks an important advance in GSK's ongoing commitment to provide new options in antiretroviral therapy for HIV patients," said Doug Manion, vice president for HIV Clinical Research for the Infectious Diseases Medicines Development Center (MDC) for GSK. "The voucher program will be particularly beneficial to people who are not covered by private health care plans or in specific states where the drug is not yet available on all formularies."

Dr. Manion added that EPZICOM provides patients and treaters with a flexible and potent dosing option that combines two NRTIs that have been widely used in antiretroviral therapy for years. "Prescribers are familiar with these medications, which have an established resistance and long-term safety p

Contact: Annie Noland
Public Communications Inc.

Page: 1 2 3 4 5

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:

(Date:10/9/2015)... ... October 09, 2015 , ... ... promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. This alternative ... invisible against the teeth, which allow patients to complete treatment in privacy. Additionally, ...
(Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation ... for Disease Control and Prevention (CDC) to improve the knowledge and skills of underserved ... been awarded a project by the CDC and allows AAFA to continue vital efforts ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... welcoming individuals from all walks of life to save money on the high ... of $25 per month per medication, individuals and families can receive their medications ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... oldest and largest recreational dispensaries in Colorado, says the latest figures on the ... rapidly and maturing into a legitimate industry. , Last month, according to ...
(Date:10/9/2015)... ... , ... Smanos was featured on NewsWatch as part of its monthly Tech ... a technology expert and special reporter for NewsWatch, conducted the review and shared with ... this day and age it’s more important than ever to keep homes and dorms ...
Breaking Medicine News(10 mins):
(Date:10/9/2015)... India , October 9, 2015 ... analysis of major players. --> ... players. --> RnRMarketResearch.com announces addition of ... status and 2020 forecasts for global markets as ... India along with analysis of major ...
(Date:10/9/2015)... 2015 Henry Schein , Inc. (NASDAQ: ... care products and services to office-based dental, animal health ... Henry Schein Disaster Relief Hotline is open for dentists, ... issues as a result of the disastrous flooding in ... for all Henry Schein customers is 800-999-9729. ...
(Date:10/9/2015)... , Oct. 9, 2015  Impax Laboratories, Inc. ... will release its third quarter 2015 financial results on ... the U.S. financial markets. The Company will host a ... at 8:30 a.m., Eastern Time on November 9, 2015.  ... . --> The financial results and live ...
Breaking Medicine Technology:
Cached News: